At close: December 13 at 4:00:02 PM EST
After hours: December 13 at 7:15:03 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 2 | 5 | 5 |
| Avg. Estimate | -1.07 | -1.1 | -3.09 | -4.06 |
| Low Estimate | -1.28 | -1.2 | -3.38 | -5.3 |
| High Estimate | -0.91 | -1 | -2.89 | -3.52 |
| Year Ago EPS | -0.32 | -0.64 | -3.36 | -3.09 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 3 | 7 | 7 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.55 | -0.65 | -0.55 | -0.74 |
| EPS Actual | -0.32 | -0.64 | -0.6 | -0.86 |
| Difference | 0.23 | 0.01 | -0.05 | -0.12 |
| Surprise % | 41.82% | 1.54% | -9.09% | -16.22% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.07 | -1.1 | -3.09 | -4.06 |
| 7 Days Ago | -1.11 | -1.2 | -3.18 | -3.87 |
| 30 Days Ago | -0.94 | -1.09 | -2.7 | -3.48 |
| 60 Days Ago | -0.94 | -1.09 | -2.7 | -3.48 |
| 90 Days Ago | -0.94 | -1.09 | -2.7 | -3.48 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | 2 | 1 | -- | 2 |
| Down Last 30 Days | 2 | 1 | 3 | 3 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| APGE | -235.16% | -71.88% | 7.92% | -31.35% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Reiterates | Guggenheim: Buy to Buy | 12/12/2024 |
| Reiterates | Guggenheim: Buy to Buy | 12/3/2024 |
| Maintains | Wedbush: Outperform to Outperform | 12/2/2024 |
| Maintains | Guggenheim: Buy to Buy | 11/27/2024 |
| Initiated | Canaccord Genuity: Buy | 11/25/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 10/25/2024 |
Related Tickers
SYRE Spyre Therapeutics, Inc.
24.12
+0.84%
NUVL Nuvalent, Inc.
86.86
+0.05%
CRNX Crinetics Pharmaceuticals, Inc.
53.66
-3.52%
WVE Wave Life Sciences Ltd.
13.44
-2.96%
ACLX Arcellx, Inc.
83.80
+0.46%
KYMR Kymera Therapeutics, Inc.
42.13
-0.09%
IRON Disc Medicine, Inc.
64.89
+0.96%
SLRN Acelyrin, Inc.
3.2300
-8.76%
KRYS Krystal Biotech, Inc.
163.64
-5.63%
ORKA Oruka Therapeutics, Inc.
21.94
+2.91%